JP2022008516A5 - - Google Patents

Download PDF

Info

Publication number
JP2022008516A5
JP2022008516A5 JP2021155065A JP2021155065A JP2022008516A5 JP 2022008516 A5 JP2022008516 A5 JP 2022008516A5 JP 2021155065 A JP2021155065 A JP 2021155065A JP 2021155065 A JP2021155065 A JP 2021155065A JP 2022008516 A5 JP2022008516 A5 JP 2022008516A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nos
amino acid
loops contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021155065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022008516A (ja
JP7336494B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2016/053185 external-priority patent/WO2017053619A1/en
Application filed filed Critical
Publication of JP2022008516A publication Critical patent/JP2022008516A/ja
Publication of JP2022008516A5 publication Critical patent/JP2022008516A5/ja
Application granted granted Critical
Publication of JP7336494B2 publication Critical patent/JP7336494B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021155065A 2015-09-23 2021-09-24 グリピカン-3結合フィブロネクチンベース足場分子 Active JP7336494B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562222633P 2015-09-23 2015-09-23
US62/222,633 2015-09-23
PCT/US2016/053185 WO2017053619A1 (en) 2015-09-23 2016-09-22 Glypican-3binding fibronectin based scafflold molecules
JP2018534505A JP6951340B2 (ja) 2015-09-23 2016-09-22 グリピカン−3結合フィブロネクチンベース足場分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018534505A Division JP6951340B2 (ja) 2015-09-23 2016-09-22 グリピカン−3結合フィブロネクチンベース足場分子

Publications (3)

Publication Number Publication Date
JP2022008516A JP2022008516A (ja) 2022-01-13
JP2022008516A5 true JP2022008516A5 (https=) 2022-05-13
JP7336494B2 JP7336494B2 (ja) 2023-08-31

Family

ID=57068233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018534505A Active JP6951340B2 (ja) 2015-09-23 2016-09-22 グリピカン−3結合フィブロネクチンベース足場分子
JP2021155065A Active JP7336494B2 (ja) 2015-09-23 2021-09-24 グリピカン-3結合フィブロネクチンベース足場分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018534505A Active JP6951340B2 (ja) 2015-09-23 2016-09-22 グリピカン−3結合フィブロネクチンベース足場分子

Country Status (7)

Country Link
US (3) US10584160B2 (https=)
EP (2) EP3733698A1 (https=)
JP (2) JP6951340B2 (https=)
KR (1) KR102818445B1 (https=)
CN (1) CN108884147B (https=)
ES (1) ES2809125T3 (https=)
WO (1) WO2017053619A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795214B (zh) 2014-03-20 2022-09-02 百时美施贵宝公司 稳定化的基于纤连蛋白的支架分子
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
ES2981335T3 (es) 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US11344639B2 (en) 2016-06-01 2022-05-31 Bristol-Myers Squibb Company PET imaging with PD-L1 binding polypeptides
KR102617252B1 (ko) 2018-05-21 2023-12-26 삼성전자주식회사 전자 장치 및 그 파노라마 촬영 모드 자동 전환 방법
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
AU2021377232A1 (en) * 2020-11-10 2023-06-15 New York University Macropinocytosis selective monobody-drug conjugates
CA3216342A1 (en) * 2021-04-23 2022-10-27 Hassan ISSAFRAS Anti-gpc3 antibodies, multispecific antibodies and methods of use
KR20260022328A (ko) * 2023-06-07 2026-02-19 레이즈바이오, 인크. 글리피칸-3을 표적화하는 방사성제약 조성물 및 그의 용도

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
EP1958962A3 (en) * 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
US6545853B1 (en) 2000-07-10 2003-04-08 Hughes Electronics Corporation Alternate grounding method
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
SI1940789T1 (sl) 2005-10-26 2012-03-30 Medarex Inc Postopki in spojine za pripravo cc analogov
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
EP2217274A1 (en) * 2007-11-28 2010-08-18 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
JP2011507543A (ja) 2007-12-27 2011-03-10 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
PL2274331T3 (pl) * 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
KR20130010461A (ko) * 2010-02-18 2013-01-28 브리스톨-마이어스 스큅 컴퍼니 Il―23에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EA022983B1 (ru) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
CA2795325A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
US9260492B2 (en) * 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
TWI812066B (zh) * 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
JP6170494B2 (ja) 2011-09-20 2017-07-26 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
KR101660146B1 (ko) 2012-02-13 2016-09-26 브리스톨-마이어스 스큅 컴퍼니 에네디인 화합물, 그의 접합체, 및 그에 대한 용도 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
TWI633117B (zh) * 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素(myostatin)以纖維連接蛋白爲主之支架結構域蛋白質
RS56169B1 (sr) 2013-02-14 2017-11-30 Bristol Myers Squibb Co Jedinjenja tubulisina, metode pripreme i primena
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
US20160000946A1 (en) * 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
CN106795214B (zh) * 2014-03-20 2022-09-02 百时美施贵宝公司 稳定化的基于纤连蛋白的支架分子
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3

Similar Documents

Publication Publication Date Title
JP2022008516A5 (https=)
RU2010147076A (ru) Аналоги инсулина специфичные к изоформам
Beck et al. Ionic interactions in the coiled-coil domain of laminin determine the specificity of chain assembly
Lin et al. The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein
Rothenstein et al. Isolation of ZnO-binding 12-mer peptides and determination of their binding epitopes by NMR spectroscopy
Zamuner et al. Design of decorated self-assembling peptide hydrogels as architecture for mesenchymal stem cells
JP2018533369A5 (https=)
ES2677844T3 (es) Péptidos para modular la actividad de linfocitos T y usos de los mismos
JP2013531477A5 (https=)
Jin et al. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1
JP2011509093A5 (https=)
Castillo et al. Self-assembled peptide nanostructures: advances and applications in nanobiotechnology
ES2362797T3 (es) Nanoarreglos de partículas biológicas, métodos para la fabricación de los mismos.
JP2024096897A5 (https=)
CN101575412B (zh) 超支化聚氨基酸及其制备方法和应用
WO2002086133A1 (fr) Additifs de milieu et milieux de culture de cellules animales
CN110129252A (zh) 一种具有细胞粘附功能的可发光胶原多肽-镧系金属复合纳米材料的制备方法
JP2004536128A5 (https=)
Masłowska et al. Synthesis, physicochemical and biological study of gallium-68-and lutetium-177-labeled VEGF-A165/NRP-1 complex inhibitors based on peptide A7R and branched peptidomimetic
JP2022517952A (ja) 分子エレクトロニクスのための伝導性合成ペプチド
JP2010521441A5 (https=)
CN119487050A (zh) 用于提高病毒转导的组合物和方法
CN103994988A (zh) 一种量子点生物探针检测多肽电荷数的方法
JP2019518713A5 (https=)
Yonath et al. Crystallography of ribosomal particles